Market capitalization | $51.57m |
Enterprise Value | $66.54m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 9.29 |
P/S ratio (TTM) P/S ratio | 7.20 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | -45.74% |
Revenue (TTM) Revenue | $7.16m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
1 Analyst has issued a forecast T2 Biosystems, Inc.:
1 Analyst has issued a forecast T2 Biosystems, Inc.:
Jun '24 |
+/-
%
|
||
Revenue | 7.16 7.16 |
46%
46%
|
|
Gross Profit | -6.40 -6.40 |
14%
14%
|
|
EBITDA | -42 -42 |
14%
14%
|
EBIT (Operating Income) EBIT | -43 -43 |
17%
17%
|
Net Profit | -48 -48 |
7%
7%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
T2 Biosystems, Inc. engages in the development of proprietary technology platform. It offers the T2 Magnetic Resonance technology, which enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types. It products include T2Bacteria Panel, T2Candida Panel, T2Dx Instrument, AND T2MR Technology. The company was founded by Michael J. Cima, Robert S. Langer Jr., Tyler Jacks, Lee Josephson, W. David Lee, and Ralph Weissleder on April 27, 2006 and is headquartered in Lexington, MA.
Head office | United States |
CEO | John Sperzel |
Employees | 113 |
Founded | 2006 |
Website | www.t2biosystems.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.